ReWalk Robotics Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ReWalk Robotics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ReWalk Robotics stock.
View analyst ratings for ReWalk Robotics or view top-rated stocks.

Wall Street analysts have given ReWalk Robotics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ReWalk Robotics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ReWalk Robotics saw a decrease in short interest in May. As of May 14th, there was short interest totaling 426,500 shares, a decrease of 43.1% from the April 29th total of 749,700 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is presently 0.2 days.
View ReWalk Robotics' Short Interest.

ReWalk Robotics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ReWalk Robotics.

ReWalk Robotics Ltd. (NASDAQ:RWLK) announced its earnings results on Tuesday, May, 11th. The medical device company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The medical device company earned $1.32 million during the quarter. ReWalk Robotics had a negative net margin of 246.47% and a negative trailing twelve-month return on equity of 40.84%.
View ReWalk Robotics' earnings history.

ReWalk Robotics' stock was trading at $0.6050 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RWLK shares have increased by 189.3% and is now trading at $1.75.
View which stocks have been most impacted by COVID-19.

1 analysts have issued twelve-month target prices for ReWalk Robotics' stock. Their forecasts range from $3.50 to $3.50. On average, they expect ReWalk Robotics' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts' price targets for ReWalk Robotics or view top-rated stocks among Wall Street analysts.

Some companies that are related to ReWalk Robotics include Invacare (IVC), Sanara MedTech (SMTI), United Health Products (UEEC), Conformis (CFMS), Lakeland Industries (LAKE), Surgalign (SRGA), Milestone Scientific (MLSS), Alpha Pro Tech (APT), Nutriband (NTRB), Myomo (MYO), Predictive Oncology (POAI), NanoVibronix (NAOV), Allied Healthcare Products (AHPI), Bionik Laboratories (BNKL) and Advanced Biomedical Technologies (ABMT).
View all of RWLK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ReWalk Robotics investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG) and Roper Technologies (ROP).

ReWalk Robotics trades on the NASDAQ under the ticker symbol "RWLK."

ReWalk Robotics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.14%), Morgan Stanley (2.33%), Virtu Financial LLC (0.12%), Renaissance Technologies LLC (0.12%), Dimensional Fund Advisors LP (0.08%) and Rhumbline Advisers (0.05%).
View institutional ownership trends for ReWalk Robotics.

RWLK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Virtu Financial LLC.
View insider buying and selling activity for ReWalk Robotics or view top insider-selling stocks.

RWLK stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Armistice Capital LLC, Dimensional Fund Advisors LP, Rhumbline Advisers, HighTower Advisors LLC, Sadoff Investment Management LLC, Sigma Planning Corp, and Jane Street Group LLC.
View insider buying and selling activity for ReWalk Robotics or or view top insider-buying stocks.

Shares of RWLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RWLK stock can currently be purchased for approximately $1.75.

ReWalk Robotics has a market capitalization of $80.71 million and generates $4.39 million in revenue each year. The medical device company earns $-12,980,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

ReWalk Robotics employs 49 workers across the globe.

The official website for ReWalk Robotics is www.rewalk.com.

ReWalk Robotics is headquartered at 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203.

ReWalk Robotics' mailing address is 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203. The medical device company can be reached via phone at 972-4959-0123 or via email at [email protected]